EMERGENT BIOSOLUTIONS INC. Contract with Customer, Asset, after Allowance for Credit Loss, Current
EMERGENT BIOSOLUTIONS INC. (EBS) had Contract with Customer, Asset, after Allowance for Credit Loss, Current of $6.40 million as of 2025-12-31, per its 10-K filed 2026-02-27.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ContractWithCustomerAssetNetCurrent · last filed 2026-02-27
- 2025-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $6.40M.
- 2024-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $9.70M.
- 2023-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $21.90M.
- 2021-12-31: Contract with Customer, Asset, after Allowance for Credit Loss, Current $21.50M.
| Period end | Contract with Customer, Asset, after Allowance for Credit Loss, Current |
|---|---|
| 2025-12-31 | $6.40M 10-K · filed 2026-02-27 |
| 2024-12-31 | $9.70M 10-K · filed 2026-02-27 |
| 2023-12-31 | $21.90M 10-K · filed 2025-03-04 |
| 2021-12-31 | $21.50M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |